Axsome Therapeutics (AXSM) vs. The Competition Financial Contrast

Axsome Therapeutics (NASDAQ:AXSM) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Axsome Therapeutics to similar companies based on the strength of its profitability, valuation, analyst recommendations, institutional ownership, earnings, risk and dividends.

Earnings & Valuation

This table compares Axsome Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Axsome Therapeutics	$865.27 million	-$183.17 million	-43.26
Axsome Therapeutics Competitors	$3.54 billion	$3.18 billion	553.85

Axsome Therapeutics’ peers have higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Axsome Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-18.18%	-198.73%	-22.03%
Axsome Therapeutics Competitors	-2,380.38%	-217.94%	-15.54%

Analyst Recommendations

This is a summary of recent ratings and price targets for Axsome Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1	2	17	1	2.86
Axsome Therapeutics Competitors	7798	13888	25778	1037	2.41

Axsome Therapeutics currently has a consensus price target of $267.58, suggesting a potential upside of 102.14%. As a group, “Pharmaceuticals” companies have a potential upside of 25.23%. Given Axsome Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than its peers.

Insider and Institutional Ownership

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Axsome Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Axsome Therapeutics’ peers have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats its peers on 9 of the 13 factors compared.

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.